Bevacizumab Plus Erlotinib Combination Therapy for Advanced Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Multicenter Retrospective Analysis in Korean Patients

Yeonjoo Choi; Bhumsuk Keam; Miso Kim; Shinkyo Yoon; Dalyong Kim; Jong Gwon Choi; Ja Young Seo; Inkeun Park; Jae Lyun Lee

doi:10.4143/crt.2019.086

Articles

Page Path: HOME > Cancer Res Treat > Volume 51(4); 2019 > Article

Original Article Bevacizumab Plus Erlotinib Combination Therapy for Advanced Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Multicenter Retrospective Analysis in Korean Patients: Yeonjoo Choi, MD¹, Bhumsuk Keam, MD, PhD¹, Miso Kim, MD¹, Shinkyo Yoon, MD², Dalyong Kim, MD³, Jong Gwon Choi, MD, PhD⁴, Ja Young Seo, MD⁵, Inkeun Park, MD, PhD^6,, Jae Lyun Lee, MD, PhD²; Cancer Research and Treatment : Official Journal of Korean Cancer Association 2019;51(4):1549-1556.
DOI: https://doi.org/10.4143/crt.2019.086
Published online: March 25, 2019

¹Division of Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea

²Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

³Division of Hematology and Medical Oncology, Dongguk University Ilsan Hospital, Ilsan, Korea

⁴Department of Internal Medicine, Konyang University Hospital, Daejeon, Korea

⁵Department of Laboratory Medicine, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea

⁶Division of Medical Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea

Correspondence: Inkeun Park, MD, PhD Division of Medical Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, 21 Namdong-daero 774beon-gil, Namdong-gu, Incheon 21565, Korea
Tel: 82-32-460-3229 Fax: 82-32-460-2391 E-mail: ingni79@gilhospital.com

• Received: February 10, 2019 • Accepted: March 23, 2019

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

8,352 Views
324 Download
40 Web of Science
41 Crossref
41 Scopus

prev next

Full Article

Download PDF

Abstract
Introduction
Materials and Methods
Results
Discussion
Electronic Supplementary Material
NOTES
REFERENCES

Abstract

Purpose
Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is a rare genetic syndrome resulting from germline mutations in fumarate hydratase. The combination of bevacizumab plus erlotinib showed promising interim results for HLRCC-associated RCC. Based on these results, we analyzed the outcome of bevacizumab plus erlotinib in Korean patients with HLRCC-associated RCC.
Materials and Methods
We retrospectively reviewed the efficacy and safety of bevacizumab plus erlotinib in patients with HLRCC-associated RCC who were confirmed to have germline mutations in fumarate hydratase. The primary endpoint was the objective response rate (ORR), while the secondary endpoints were progression-free survival (PFS) and overall survival (OS).
Result
We identified 10 patients with advanced HLRCC-associated RCC who received bevacizumab plus erlotinib. Median age at diagnosis was 41 years, and five of the patients had received the combination as first- or second-line treatments. The ORR was 50% and the median PFS and OS were 13.3 and 14.1 months, respectively. Most adverse events were predictable and manageable by conventional measures, except for one instance where a patient died of gastrointestinal bleeding.
Conclusion
This is the first real-world outcome of the treatment of advanced HLRCC-associated RCC. Bevacizumab plus erlotinib therapy showed promising activity with moderate toxicity. We should be increasingly aware of HLRCC-associated RCC and bevacizumab plus erlotinib should be a first-line treatment for this condition, unless other promising data are published.
Key words: Hereditary leiomyomatosis and renal cell carcinoma, Bevacizumab, Erlotinib, Renal cell carcinoma, Fumarate hydratase, Non-clear cell

Introduction

Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome is a genetic syndrome resulting from germline mutations in fumarate hydratase (FH) [1]. This autosomal dominant condition is characterized by cutaneous leiomyomas, early-onset multiple uterine leiomyomas, and an aggressive form of type 2 papillary renal cell carcinoma (RCC) [2,3]. Although RCC arising in HLRCC syndrome has been described as type 2 papillary RCC, the recently updated World Health Organization (WHO) 2016 genitourinary cancer classification added RCC in HLRCC as a new entity, HLRCC-associated RCC [4].

More than 180 families with FH germline mutations have been reported [3] but the exact incidence of HLRCC syndrome or HLRCC-associated RCC remains unknown as this entity has had a low awareness among urologists, medical oncologists, and pathologists until today. A considerable proportion of patients with HLRCC-associated RCC might have been diagnosed and treated as having sporadic papillary RCC and even after correct diagnosis, there has been no specific treatment option for advanced HLRCC-associated RCC. The most commonly used treatment might be mammalian target of rapamycin (mTOR) inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR TKIs), similar to the treatment of non-clear cell RCC [5].

With the accumulation of pathobiological knowledge underlying HLRCC-associated RCC, there have been attempts at mechanism-based treatment for HLRCC-associated RCC. FH-deficient kidney cancer is characterized by impaired Krebs cycle and oxidative phosphorylation, thus depends on glucose for adenosine triphosphate generation by aerobic glycolysis (Warburg effect). Increased oxidative stress and/or increased levels of fumarate inhibit hypoxia-inducible factor (HIF) prolyl hydroxylase which facilitates ubiquitinmediated degradation of HIF, resulting in HIF stabilization. Accumulation of HIF leads to increased transcription of vascular endothelial growth factor (VEGF) [2]. Bevacizumab can inhibit VEGF-mediated tumor vasculature. In a meanwhile, epidermal growth factor receptor (EGFR) signaling promotes aerobic glycolysis through the phosphoinositide 3-kinase/AKT or RAS/ mitogen-activated protein kinase pathway [6], and EGFR TKI erlotinib reverted aerobic glycolysis in cancer cell line [7].

Against this backdrop, phase II clinical trials evaluating the efficacy and safety of the combination of bevacizumab plus erlotinib (AVATAR trial, NCT01130519) and the combination of vandetanib plus metformin (NCT02495103) are underway. An interim analysis of the AVATAR trial of bevacizumab plus erlotinib showed an impressive objective response rate (ORR) of 65% in patients with HLRCC-associated RCC [8] and a median progression-free survival (PFS) of 24.2 months. This promising result led to the recommendation of bevacizumab plus erlotinib for the treatment of HLRCC-associated RCC in the 2018 National Comprehensive Cancer Network (NCCN) guidelines [9].

In Korea, however, HLRCC-associated RCC has only recently been recognized by physicians and, to our knowledge, there are currently no formal reports on Korean patients with this disease. Therefore, the outcome of bevacizumab plus erlotinib therapy in Korean patients is not known. For this reason, we retrospectively collected data on patients with HLRCC in Korea and to evaluate the efficacy and safety of the bevacizumab plus erlotinib combination treatment.

Materials and Methods

1. Patient selection

We retrospectively reviewed consecutive patients diagnosed with HLRCC-associated RCC and treated between July 2014 and July 2018 in three academic hospitals (Asan Medical Center, Gil Medical Center, and Seoul National University Hospital) in South Korea. The selection criteria for analysis were as follows: diagnosis of HLRCC-associated RCC, advanced stage (recurrent, locoregionally advanced unresectable, or metastatic disease), treatment with bevacizumab (10 mg/kg every 2 weeks intravenously) plus erlotinib (150 mg p.o daily) for HLRCC-associated RCC irrespective of line of treatment, and adequate clinical information and baseline and follow-up imaging.

Definitive diagnosis of HLRCC-associated RCC was confirmed by FH germline mutation test by polymerase chain reaction (PCR)–based sequencing methods from peripheral blood leukocytes. The criteria for proceeding to germline FH tests were as follows: suggestion of HLRCC-associated RCC in pathologic examination, diagnosis of papillary-type RCC under 40 years of age, pathologically confirmed cutaneous leiomyomatosis, multiple early-onset symptomatic uterine myoma in female patients or in family members of male patients, or family history of HLRCC syndrome.

2. Data collection and analysis

We collected the clinicopathological data of these patients from electronic medical record systems. Data on their baseline demographic characteristics, radiologic response and time-to-progression (TTP) to previous systemic treatments and bevacizumab plus erlotinib, adverse events related to bevacizumab plus erlotinib, and survival data were also gathered. Response evaluation according to Response Evaluation Criteria in Solid Tumors ver. 1.1 was performed by a comprehensive review of baseline and follow-up imaging. Usual radiographic evaluations were assessed every 2-3 months by computed tomography of the chest, abdomen, and pelvis but other image techniques were used at the discretion of the attending physicians. Safety was evaluated according to the Common Terminology Criteria for Adverse Events ver. 4.0, from the National Cancer Institute.

3. Statistical analysis

Patient characteristics and toxicity were summarized descriptively. The primary endpoint was ORR and the secondary endpoints were PFS, OS, and safety. Kaplan-Meier analysis was used to determine the time-to-event endpoints. PFS was defined as the time from treatment initiation to the date of documentation of disease progression or death from any cause, whichever came first, while OS was calculated as the time from treatment initiation to death from any cause. Cases in which progression and/or death did not occur were censored at the date of the last follow-up. All statistical analyses were performed using IBM SPSS Statistics for Windows ver. 25.0 (IBM Corp., Armonk, NY).

4. Ethical statement

All procedures were conducted in accordance with the ethical standards of the institutional and/or national research committee and with the Helsinki declaration. This study was approved by the Institutional Review Board of each hospital (GAIRB2017-365). IRB waived informed consent for this study because of its nature of retrospective analysis.

Results

1. Patient characteristics

We identified 10 patients confirmed to have HLRCC-associated with RCC by FH germline mutation who received bevacizumab and erlotinib. Their basic demographic information is shown in Table 1. The median age was 41 years (range, 27 to 52 years) and nine patients (90%) were male. None were diagnosed with HLRCC-associated RCC by histologic examination at the time of initial diagnosis of RCC; that is to say, all cases of HLRCC-associated RCC were diagnosed by clinical suspicion and subsequent germline FH mutation testing. Seven patients (70%) had locally advanced or metastatic disease at the time of initial diagnosis and radical nephrectomy was performed in six patients (60%). The most common metastatic sites were lymph nodes, liver, and bone.

Five of the ten patients (50%) received bevacizumab plus erlotinib as first- or second-line treatments, while five patients (50%) received the combination as third-line or later. The majority of patients belonged to the intermediate or poor-risk groups according to the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).

2. Systemic treatments for advanced disease

Table 2 summarizes the history of systemic treatments and their outcomes. Among first-line treatments, five of the ten patients started with temsirolimus, one patient with sunitinib, and four patients with bevacizumab and erlotinib. Four patients treated with first-line temsirolimus showed no objective response, with a median TTP of 2.3 months. Four of them received axitinib as the second-line therapy, with ORR and TTP of 50% and 9.2 months, respectively. One patient (case 1) achieved a long-term response with axitinib lasting about 25 months. Overall, VEGFR TKIs demonstrated favorable efficacy in a subset of patients, while mTOR inhibitors did not. Regarding immune checkpoint inhibitor therapy, three patients received ipilimumab plus nivolumab (cases 1 and 2) or nivolumab (case 9) but they did not obtain any efficacy. Case 1 also received nivolumab plus pazopanib which were sustained for 6 months.

3. Efficacy of bevacizumab and erlotinib

For the patients who received bevacizumab plus erlotinib as second or more line of treatment, the median time from the first-line treatment to the initiation of bevacizumab plus erlotinib was 7.8 months. Among 10 included patients, nine patients underwent at least one response evaluation. Bevacizumab plus erlotinib resulted in a partial response in five patients (50%), stable disease in four patients (40%), and not evaluable in one (10%), with the ORR of 50% (95% confidence interval [CI], 24 to 76) and disease control rate of 90% (95% CI, 60 to 98) (Table 3, Fig. 1). The estimated median PFS was 13.3 months (95% CI, 0.0 to 26.9) (Fig. 2). Two patients (cases 2 and 5) continued bevacizumab plus erlotinib beyond radiologic disease progression at the discretion of the treating physicians because the speed of progression was slow, and the patients maintained good general conditions. Case 2 received bevacizumab plus erlotinib for an additional 9.2 months. The estimated median OS was 14.1 months (95% CI, not calculated) (Fig. 2).

4. Safety profile of bevacizumab plus erlotinib

All patients experienced any grade adverse events during treatment (Table 4). There were no unexpected toxicities. The most common event was acneiform eruption (70%), followed by hypertension (50%), proteinuria (40%), alanine aminotransferase elevation (40%), and dry skin (40%). Grade 1 or 2 fatigue and diarrhea occurred one-third of the patients. These events were tolerable and managed with conventional supportive care. All patients continued treatment. However, one patient (case 7) died of gastrointestinal bleeding, which was not associated with disease progression but may have been an adverse event related to bevacizumab.

Discussion

To our knowledge, this is the first report of treatment outcomes not only in Korean patients diagnosed with HLRCC-associated RCC by germline genetic testing but also in realworld practice. We confirmed that the combination of bevacizumab and erlotinib is effective and safe. The ORR was 50% and the median PFS and OS were 13.3 and 14.1 months, respectively. Adverse events were mostly predictable and manageable with routine supportive measures.

HLRCC-associated RCC was only recently categorized by WHO as a distinct entity; therefore, knowledge regarding its clinical features and prognosis is limited. In contrast to other hereditary RCC syndromes, HLRCC-associated RCC is usually unilateral and solitary and metastasis can occur even if primary lesion measures less than 1 cm [2,10]. It usually develops in younger people, predominantly between the ages of 15 and 29 years, but can affect patients as young as 11 years [11]. In our study, the median age at diagnosis was 41 years (range, 27 to 52 years), similar to those in previous reports [12]. More than half of the patients in the present study had advanced disease at the time of diagnosis. The most common metastatic sites were lymph nodes (abdominal or thoracic), bone, and liver. None of our patients were suspected of having HLRCC-associated RCC by histologic examination. Clinical suspicion is important for a correct diagnosis; thus, physicians may be clued to suspicion by family history, presence of uterine myomas, skin lesions, and clinical course.

Early detection and prompt surgical extirpation can cure the condition, while the prognosis is very poor at advanced stages [13]. There has been no standard of care for metastatic HLRCC-associated RCC because definitive diagnosis is difficult and its rarity has precluded clinical trials. Thus far, AVATAR is the only clinical trial with promising results for the combination of bevacizumab plus erlotinib. In the interim analysis, the response rates were approximately 29% and 65% for papillary RCC without and with FH mutations, respectively. The median PFS in our group was shorter than that in a previous report (13.3 months vs. 24.2 months) [8], probably because patients with adverse features were included in our analysis. Furthermore, the small number and frequent censoring of the current study make the survival analysis less reliable.

All patients who received systemic treatment before 2018 started with mTOR inhibitor or VEGFR TKIs, according to clinical practice for non-clear cell RCCs. For these patients, bevacizumab plus erlotinib was administered in later lines. In contrast, four out of five patients diagnosed with metastatic disease in 2018 received bevacizumab and erlotinib as first-line treatment. The reason for the early initiation of bevacizumab plus erlotinib was the physician’s awareness of this entity and guideline recommendation for this treatment. It is not clear whether patients treated with bevacizumab plus erlotinib as an initial treatment showed a better response rate and PFS than those in patients who had received other treatments before bevacizumab plus erlotinib. However, before other promising data are published, bevacizumab and erlotinib should be a standard treatment for HLRCC-associated RCC.

The adverse events of bevacizumab plus erlotinib treatment were mostly manageable. The most common adverse events were acneiform eruption, hypertension, proteinuria, liver function abnormality, and dry skin. Other constitutional symptoms such as fatigue, anorexia, or insomnia also occurred. One patient died of severe intestinal bleeding, which was deemed a complication of the bevacizumab. Therefore, although medical oncologists are familiar with the complications of both erlotinib and bevacizumab, care should be taken to detect potentially life-threatening complications.

In many cancers where targeted therapies like VEGF inhibitor or EGFR inhibitors are frequently used, adverse events attributable to the mechanism of action of molecular targeted agents have been increasingly suggested as predictive biomarker for efficacy [14,15]. We explored whether acneiform eruption, hypertension, or proteinuria could be a predictive marker for PFS. Median PFS was 6.5 (95% CI, 0 to 15.5) and 13.4 (95% CI, 0 to 27.4) for patients without and with acneiform eruption, respectively (p=0.36). In addition, median PFS was 6.2 months (95% CI, 1.7 to 10.6) and 21.3 months (95% CI, not calculated) for patients without and with hypertension (p=0.023), and 6.2 months (95% CI, 1.9 to 10.5) and 21.3 months (95% CI not calculated) for patients without and with proteinuria (p=0.029) (S1 Fig.). To confirm the predictive role of these biomarkers, validation in larger homogeneous prospective cohort (like the AVATAR trial) is needed.

Several prerequisites are essential to improving the clinical practice of HLRCC-associated RCC. Most importantly, physicians should be aware of HLRCC-associated RCC to properly diagnose and treat this disease. Although we reported patients with advanced-stage disease, it is important to detect and cure at early stages. Therefore, genetic counseling and screening of all family members are needed. Furthermore, active surveillance should be performed for early diagnosis of RCC in FH mutation carriers. This strategy has been suggested by the Kidney Cancer Research Network of Canada [16]. Additionally, the medical costs for genetic testing, surveillance, and treatment of HLRCC are currently not covered by the national health care insurance system in Korea. This financial burden might preclude families with FH mutations from proper and timely treatment and newly-detected families with this rare hereditary cancer syndrome comprise an urgent unmet medical needs in Korea.

This study has several limitations. Above all, this retrospective study included a small number of patients from three academic hospitals. Even though the three hospitals are among the largest in Korea, additional patients may have been diagnosed with HLRCC-associated RCC and received bevacizumab plus erlotinib. Second, there was no central pathology review. However, all participating centers were academic centers possessing genitourinary pathology specialists experienced in RCC. Finally, the PCR for FH was not centralized and was performed in each institution by laboratory-developed tests.

In conclusion, this is the first report on the treatment of advanced HLRCC-associated RCC in real-world practice. Bevacizumab plus erlotinib therapy was effective and the safety profiles were predictable and manageable. Physicians participating in the management of genitourinary cancer should be aware of HLRCC-associated RCC to properly diagnose and treat this disease. Considering its efficacy and safety, bevacizumab plus erlotinib should be the standard of treatment, unless other promising data are published.

Electronic Supplementary Material

Supplementary materials are available at Cancer Research and Treatment website (https://www.e-crt.org).

crt-2019-086-suppl1.pdf

NOTES

Conflict of interest relevant to this article was not reported.

Fig. 1.

Waterfall plots depicting change from baseline in sum of diameters for target lesions in patients with hereditary leiomyomatosis and renal cell carcinoma–associated renal cell carcinoma treated with bevacizumab plus erlotinib (n=9). SD, stable disease; PR, partial response.

Fig. 2.

Kaplan-Meier curve for progression-free survival (PFS) and overall survival (OS) in patient with hereditary leiomyomatosis and renal cell carcinoma–associated renal cell carcinoma treated with bevacizumab plus erlotinib.

Table 1.

Baseline patient characteristics

Characteristic	No. (%) (n=10)
Age, median (range, yr)	41 (27-52)
Sex
Male	9 (90)
Female	1 (10)
Tumor histology at the time of initial diagnosis
Papillary RCC	8 (80)
Non-classified	2 (20)
Disease status at the time of initial diagnosis
Localized	3 (30)
Locally advanced	2 (20)
Metastatic	5 (50)
Nephrectomy	6 (60)
Line of bevacizumab and erlotinib
1st	4 (40)
2nd	1 (10)
3rd or more	5 (50)
IMDC prognostic group
Favorable	1 (10)
Intermediate	5 (50)
Poor	4 (40)
Karnofsky performance status (%)
100-90	2 (20)
80-70	5 (50)
< 70	3 (30)
Metastatic sites
Lymph nodes	9 (90)
Liver	8 (80)
Bone	7 (70)
Lung	6 (60)
Adrenal gland	3 (30)
No. of metastatic organs
1	0
2	3 (30)
3	1 (10)
4 or more	6 (60)

RCC, renal cell carcinoma; IMDC, International Metastatic Renal Cell Carcinoma Database Consortium.

Table 2.

History of systemic treatments and their outcomes

No.	Dx/Tx year	1st line	BR	TTP (mo)	2nd line	BR	TTP (mo)	3rd line	BR	TTP (mo)	4th line	BR	TTP (mo)	5th line	BR	TTP (mo)
1	2012/2013	Tem	PD	2.5	Axi	PR	24.8	Bev/Erlo	SD	6.5	Nivo/Pazo	SD	6.0	Ipi/Nivo	PD	0.2
2	2014/2014	Tem	PD	1.0	Axi	PD	0.6	Gem/Cis	PD	1.2	Ipi/Nivo	PD	0.5	Bev/Erlo	SD	4.1^a)
3	2015/2015	Tem	SD	4.8	Axi	PD	1.7	Bev/Erlo	PR	21.3	-	-	-	-	-	-
4	2015/2016	Tem	PD	2.3	Axi	PR	9.7	Bev/Erlo	SD	16.3+	-	-	-	-	-	-
5	2016/2018	Bev/Erlo	SD	6.1^a)	-	-	-	-	-	-	-	-	-	-	-	-
6	2017/2017	Sun	SD	5.5	Bev/Erlo	PR	13.3	-	-	-	-	-	-	-	-	-
7	2018/2018	Bev/Erlo	NE	0.6^b)	-	-	-	-	-	-	-	-	-	-	-	-
8	2018/2018	Bev/Erlo	PR	6.6+	-	-	-	-	-	-	-	-	-	-	-	-
9	2018/2018	Tem	PD	2.1	Nivo	PD	1.7	Bev/Erlo	PR	1.94+	-	-	-	-	-	-
10	2018/2018	Bev/Erlo	PR	11.0+	-	-	-	-	-	-	-	-	-	-	-	-

Dx, initial diagnosis; Tx, systemic treatment; BR, best response; TTP, time-to-progression; Tem, temsirolimus; PD, progressive disease; Axi, axitinib; PR, partial response; Bev, bevacizumab; Erlo, erlotinib; SD, stable disease; Nivo, nivolumab; Pazo, pazopanib; Ipi, ipilimumab; Gem, gemcitabine; Cis, cisplatin; Sun, sunitinib; NE, not evaluated.

^a) The patients were treated with bevacizumab plus erlotinib beyond radiologic progression for 9.2 months (case 2) and 0.4 month (case 5), respectively,

^b) The patient died of gastrointestinal bleeding without disease progression.

Table 3.

Treatment efficacy of bevacizumab plus erlotinib in patients with HLRCC-associated RCC (n=10)

	Value
Best overall response, n (%)
CR	0
PR	5 (50)
SD	4 (40)
PD	0
NE	1 (10)
ORR (95% CI, %)	50 (24-76)
DCR (95% CI, %)	90 (60-98)
Median PFS (95% CI, mo)	13.3 (0.0-26.9)
Median OS (mo)^a)	14.1

HLRCC, hereditary leiomyomatosis and renal cell carcinoma syndrome; RCC, renal cell carcinoma; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; NE, not evaluable; ORR, objective response rate; CI, confidence interval; DCR, disease control rate; PFS, progression-free survival; OS, overall survival.

^a) The 95% CI was not calculated due to small number of events.

Table 4.

Adverse events of bevacizumab and erlotinib (n=10)

	Any grade	Grade 3 or more
Any adverse event	10 (100)	2 (20)
Hematologic toxicity
Anemia	2 (20)	0
Neutropenia	0	0
Thrombocytopenia	0	0
Non-hematologic toxicity
Acneiform eruption	7 (70)	1 (10)
Hypertension	5 (50)	0
Proteinuria	4 (40)	0
ALT increased	4 (40)	0
Dry skin	4 (40)	0
Diarrhea	3 (30)	0
Fatigue	3 (30)	0
Creatinine increased	3 (30)	0
Mucositis, oral	2 (20)	0
Anorexia	2 (20)	0
Insomnia	2 (20)
Hyperbilirubinemia	1 (10)	0
Gastrointestinal bleeding	1 (10)	1 (10)^a)
Dry eye	1 (10)	0
Neuropathy	1 (10)	0
Wound dehiscence	1 (10)	0
Epistaxis	1 (10)	0
Hand-foot syndrome	1 (10)	0

Values are presented as number (%). ALT, alanine aminotransferase.

^a) The patient died of grade 5 gastrointestinal bleeding.

REFERENCES

1. Tomlinson IP, Alam NA, Rowan AJ, Barclay E, Jaeger EE, Kelsell D, et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet. 2002;30:406–10. Article PubMed PDF
2. Linehan WM, Rouault TA. Molecular pathways: Fumarate hydratase-deficient kidney cancer: targeting the Warburg effect in cancer. Clin Cancer Res. 2013;19:3345–52. Article PubMed PMC
3. Lehtonen HJ. Hereditary leiomyomatosis and renal cell cancer: update on clinical and molecular characteristics. Fam Cancer. 2011;10:397–411. Article PubMed PDF
4. Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours. Eur Urol. 2016;70:93–105. Article PubMed
5. Srinivasan R, Ricketts CJ, Sourbier C, Linehan WM. New strategies in renal cell carcinoma: targeting the genetic and metabolic basis of disease. Clin Cancer Res. 2015;21:10–7. Article PubMed PMC
6. Yang L, Xie M, Yang M, Yu Y, Zhu S, Hou W, et al. PKM2 regulates the Warburg effect and promotes HMGB1 release in sepsis. Nat Commun. 2014;5:4436.Article PubMed PMC PDF
7. De Rosa V, Iommelli F, Monti M, Fonti R, Votta G, Stoppelli MP, et al. Reversal of Warburg effect and reactivation of oxidative phosphorylation by differential inhibition of EGFR signaling pathways in non-small cell lung cancer. Clin Cancer Res. 2015;21:5110–20. Article PubMed
8. Srinivasan R, Su D, Stamatakis L, Siddiqui MM, Singer E, Shuch B, et al. 5 Mechanism based targeted therapy for hereditary leiomyomatosis and renal cell cancer (HLRCC) and sporadic papillary renal cell carcinoma: interim results from a phase 2 study of bevacizumab and erlotinib. Eur J Cancer. 2014;50(Suppl 6):8.Article
9. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Kidney cancer (ver 2. 2019) [Internet]. National Comprehensive Cancer Network; 2019. Available from: https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf
10. Grubb RL 3rd, Franks ME, Toro J, Middelton L, Choyke L, Fowler S, et al. Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer. J Urol. 2007;177:2074–9. Article PubMed
11. Alrashdi I, Levine S, Paterson J, Saxena R, Patel SR, Depani S, et al. Hereditary leiomyomatosis and renal cell carcinoma: very early diagnosis of renal cancer in a paediatric patient. Fam Cancer. 2010;9:239–43. Article PubMed PDF
12. Merino MJ, Torres-Cabala C, Pinto P, Linehan WM. The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome. Am J Surg Pathol. 2007;31:1578–85. Article PubMed
13. Menko FH, Maher ER, Schmidt LS, Middelton LA, Aittomaki K, Tomlinson I, et al. Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment. Fam Cancer. 2014;13:637–44. Article PubMed PMC PDF
14. Dienstmann R, Brana I, Rodon J, Tabernero J. Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs. Oncologist. 2011;16:1729–40. Article PubMed PMC
15. Sorich MJ, Rowland A, Kichenadasse G, Woodman RJ, Mangoni AA. Risk factors of proteinuria in renal cell carcinoma patients treated with VEGF inhibitors: a secondary analysis of pooled clinical trial data. Br J Cancer. 2016;114:1313–7. Article PubMed PMC PDF
16. Lattouf JB, Pautler SE, Reaume MN, Kim RH, Care M, Green J, et al. Structured assessment and followup for patients with hereditary kidney tumour syndromes. Can Urol Assoc J. 2016;10:E214–22. Article PubMed PMC

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

A Phase 2 Trial of Talazoparib and Avelumab in Genomically Defined Metastatic Kidney Cancer
Ritesh R. Kotecha, Sahil D. Doshi, Andrea Knezevic, Joshua Chaim, Yingbei Chen, Rachel Jacobi, Mark Zucker, Ed Reznik, Deaglan McHugh, Neil J. Shah, Emily Feld, David H. Aggen, William Rafelson, Han Xiao, Maria I. Carlo, Darren R. Feldman, Chung-Han Lee,
European Urology Oncology.2024; 7(4): 804. CrossRef
Hereditary Renal Cancer Syndromes
Grigory A. Yanus, Ekaterina Sh. Kuligina, Evgeny N. Imyanitov
Medical Sciences.2024; 12(1): 12. CrossRef
Fumarate Hydratase-Deficient Renal Cell Carcinoma—A Clinicopathological Study of a Series of 11 Cases
Aswathy A. Menon, Swapnil Rane, Uma Sakhadeo, Gagan Prakash, Amit Joshi, Mahendra Pal, Amandeep Arora, Nilesh Sable, Aparna Katdare, Palak Popat, Priyamvada Maitre, Archi Agarwal, Vedang Murthy, Sangeetha B. Desai, Santosh Menon
Indian Journal of Medical and Paediatric Oncology.2024;[Epub] CrossRef
Memory/Active T-Cell Activation Is Associated with Immunotherapeutic Response in Fumarate Hydratase–Deficient Renal Cell Carcinoma
Junru Chen, Xu Hu, Junjie Zhao, Xiaoxue Yin, Linmao Zheng, Jingjing Guo, Jianhui Chen, Yongquan Wang, Xinan Sheng, Haiying Dong, Xiaodong Liu, Xingming Zhang, Jiayu Liang, Haolin Liu, Jin Yao, Jiyan Liu, Yali Shen, Zhibin Chen, Zhengyu He, Yaodong Wang, N
Clinical Cancer Research.2024; 30(11): 2571. CrossRef
Comparison of Primary and Metastatic Fumarate Hydratase-Deficient Renal Cell Carcinomas Documents Morphologic Divergence and Potential Diagnostic Pitfall With Peritoneal Mesothelioma
Anna Caliò, Stefano Marletta, Lavinia Stefanizzi, Lisa Marcolini, Matteo Rotellini, Gabriella Serio, Elena Bariani, Caterina Vicentini, Serena Pedron, Filippo M. Martelli, Pietro Antonini, Matteo Brunelli, Guido Martignoni
Modern Pathology.2024; 37(9): 100561. CrossRef
Bevacizumab-Based Therapies in Malignant Tumors—Real-World Data on Effectiveness, Safety, and Cost
Elena Chitoran, Vlad Rotaru, Sinziana-Octavia Ionescu, Aisa Gelal, Cristina-Mirela Capsa, Roxana-Elena Bohiltea, Madalina-Nicoleta Mitroiu, Dragos Serban, Giuseppe Gullo, Daniela-Cristina Stefan, Laurentiu Simion
Cancers.2024; 16(14): 2590. CrossRef
Clinical Practice Recommendations for the Use of Next-Generation Sequencing in Patients with Solid Cancer: A Joint Report from KSMO and KSP
Miso Kim, Hyo Sup Shim, Sheehyun Kim, In Hee Lee, Jihun Kim, Shinkyo Yoon, Hyung-Don Kim, Inkeun Park, Jae Ho Jeong, Changhoon Yoo, Jaekyung Cheon, In-Ho Kim, Jieun Lee, Sook Hee Hong, Sehhoon Park, Hyun Ae Jung, Jin Won Kim, Han Jo Kim, Yongjun Cha, Sun
Cancer Research and Treatment.2024; 56(3): 721. CrossRef
Clinical practice recommendations for the use of next-generation sequencing in patients with solid cancer: a joint report from KSMO and KSP
Miso Kim, Hyo Sup Shim, Sheehyun Kim, In Hee Lee, Jihun Kim, Shinkyo Yoon, Hyung-Don Kim, Inkeun Park, Jae Ho Jeong, Changhoon Yoo, Jaekyung Cheon, In-Ho Kim, Jieun Lee, Sook Hee Hong, Sehhoon Park, Hyun Ae Jung, Jin Won Kim, Han Jo Kim, Yongjun Cha, Sun
Journal of Pathology and Translational Medicine.2024; 58(4): 147. CrossRef
Complete response to fifth-line anti-PD-1 rechallenge in fumarate hydratase-mutated papillary renal cell carcinoma
Isabella Portugal, Maria A. Clavijo-Salomon
npj Precision Oncology.2024;[Epub] CrossRef
Genomic Profiling and Response to Immune Checkpoint Inhibition plus Tyrosine Kinase Inhibition in FH-Deficient Renal Cell Carcinoma
Yunze Xu, Wen Kong, Ming Cao, Jieying Wang, Zaoyu Wang, Liang Zheng, Xiaoyu Wu, Rongrong Cheng, Wei He, Bo Yang, Baijun Dong, Jiahua Pan, Yonghui Chen, Jiwei Huang, Chen Jiang, Wei Zhai, Fangzhou Li, Ruohua Chen, Xiang Zhou, Guangyu Wu, Xiaochuan Geng, Ji
European Urology.2023; 83(2): 163. CrossRef
Navigating the Current Landscape of Non-Clear Cell Renal Cell Carcinoma: A Review of the Literature
Alexius John, Lavinia Spain, Anis A. Hamid
Current Oncology.2023; 30(1): 923. CrossRef
CLC-Pred 2.0: A Freely Available Web Application for In Silico Prediction of Human Cell Line Cytotoxicity and Molecular Mechanisms of Action for Druglike Compounds
Alexey A. Lagunin, Anastasia V. Rudik, Pavel V. Pogodin, Polina I. Savosina, Olga A. Tarasova, Alexander V. Dmitriev, Sergey M. Ivanov, Nadezhda Y. Biziukova, Dmitry S. Druzhilovskiy, Dmitry A. Filimonov, Vladimir V. Poroikov
International Journal of Molecular Sciences.2023; 24(2): 1689. CrossRef
Fumarate Hydratase-deficient Renal Cell Carcinoma
Yi-Hsuan Huang, Nan-Haw Chow, Yu-Ting Yu, Wen-Pin Su
Journal of Cancer Research and Practice.2023; 10(1): 28. CrossRef
Diseases of Hereditary Renal Cell Cancers
Othon Iliopoulos
Urologic Clinics of North America.2023; 50(2): 205. CrossRef
Hereditary Leiomyomatosis and Renal Cell Cancer: A Case Report of Pilar Leiomyomatosis with History of Kidney Cancer and Review of the Literature
Jee-Woo Kim, Jung-Won Shin, Anna Cho, Chang-Hun Huh
Annals of Dermatology.2023;[Epub] CrossRef
Clinical Characteristics of Molecularly Defined Renal Cell Carcinomas
Xinfeng Hu, Congzhu Tan, Guodong Zhu
Current Issues in Molecular Biology.2023; 45(6): 4763. CrossRef
Hereditary predisposition to kidney cancer: cancer syndromes, multisystemic disorders, and nephropathies
G. A. Yanus, A. G. Iyevleva, E. N. Suspitsin, A. V. Tumakova, E. V. Belogubova, S. N. Aleksakhina, A. V. Togo, E. N. Imyanitov
Sechenov Medical Journal.2023; 14(2): 5. CrossRef
Hereditary leiomyomatosis and renal cell cancer associated with metastatic rectal cancer
Parikshit Padhi, Naga Praneeth Raja
Current Problems in Cancer: Case Reports.2023; 11: 100257. CrossRef
Unmasking the enigma: A case of Fumarate Hydratase-deficient renal cell carcinoma
Mirza Rameez Samar, Wajiha Khan, Yasmin Abdul Rashid, Azmina Tajuddin Vali Mohammad
International Journal of Surgery Case Reports.2023; 113: 109054. CrossRef
Tumors masquerading as type 2 papillary renal cell carcinoma: pathologists’ ever-expanding differential diagnosis for a heterogeneous group of entities
Alexander S. Taylor, Stephanie L. Skala
Urologic Oncology: Seminars and Original Investigations.2022; 40(12): 499. CrossRef
Low-Grade Fumarate Hydratase-Deficient Renal Cell Carcinoma in a 30-Year-Old Female
Nicolas Wyvekens, William J. Anderson, Young X. Kim, Mark Carter, Michelle S. Hirsch
International Journal of Surgical Pathology.2022; 30(2): 184. CrossRef
Response to the Letter to the Editor Entitled “Do We Have Sufficient Evidence to Define Prognosis for ‘Low-grade’ Fumarate Hydratase-deficient Renal Cell Carcinoma?”
Steven C. Smith, Ameer Hamza, Deepika Sirohi, Mahul B. Amin
Advances in Anatomic Pathology.2022; 29(3): 181. CrossRef
Hereditary Renal Cell Carcinoma
Scott J. Dawsey, Shilpa Gupta
Kidney Cancer.2022; 6(2): 83. CrossRef
A Phase II, Single-arm Trial of Sunitinib and Erlotinib in Advanced Renal Cell Carcinoma
Zizhen Feng, Brendan D. Curti, David I. Quinn, John M. Strother, Zunqiu Chen, Rebecca Agnor, Tomasz M. Beer, Christopher W. Ryan
Clinical Genitourinary Cancer.2022; 20(5): 415. CrossRef
Targeting strategies in the treatment of fumarate hydratase deficient renal cell carcinoma
Andrea Katharina Lindner, Gennadi Tulchiner, Andreas Seeber, Peter J. Siska, Martin Thurnher, Renate Pichler
Frontiers in Oncology.2022;[Epub] CrossRef
MR Spectroscopy for Detecting Fumarate Hydratase Deficiency in Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome
Guangyu Wu, Guiqin Liu, Jianfeng Wang, Shihang Pan, Yuansheng Luo, Yunze Xu, Wen Kong, Peng Sun, Jianrong Xu, Wei Xue, Jin Zhang
Radiology.2022; 305(3): 631. CrossRef
Complete response of hereditary leiomyomatosis and renal cell cancer (HLRCC)-associated renal cell carcinoma to nivolumab and ipilimumab combination immunotherapy by: a case report
Yasuhiro Iribe, Mitsuko Furuya, Yousuke Shibata, Masato Yasui, Makoto Funahashi, Junichi Ota, Hiromichi Iwashita, Yoji Nagashima, Hisashi Hasumi, Narihiko Hayashi, Kazuhide Makiyama, Keiichi Kondo, Reiko Tanaka, Masahiro Yao, Noboru Nakaigawa
Familial Cancer.2021; 20(1): 75. CrossRef
Genotypic and Phenotypic Characteristics of Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome in Korean Patients
Ja Young Seo, Jeong-Yeal Ahn, Bhumsuk Keam, Miso Kim, Shinkyo Yoon, Jae Lyun Lee, Kwonoh Park, Inkeun Park
Annals of Laboratory Medicine.2021; 41(2): 207. CrossRef
Integrated Molecular Characterization of Fumarate Hydratase–deficient Renal Cell Carcinoma
Guangxi Sun, Xingming Zhang, Jiayu Liang, Xiuyi Pan, Sha Zhu, Zhenhua Liu, Cameron M. Armstrong, Jianhui Chen, Wei Lin, Banghua Liao, Tianhai Lin, Rui Huang, Mengni Zhang, Linmao Zheng, Xiaoxue Yin, Ling Nie, Pengfei Shen, Jinge Zhao, Haoran Zhang, Jindon
Clinical Cancer Research.2021; 27(6): 1734. CrossRef
Durable Major Response With Pazopanib in Recurrent, Heavily Pretreated Metastatic Esthesioneuroblastoma Harboring a Fumarate Hydratase Mutation
Marianne Spengler, Megan Wheelden, Heath B. Mackley, Joseph J. Drabick
JCO Precision Oncology.2021; (5): 664. CrossRef
Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma
Andrew J. Wiele, Devaki Shilpa Surasi, Priya Rao, Kanishka Sircar, Xiaoping Su, Tharakeswara K. Bathala, Amishi Y. Shah, Eric Jonasch, Vince D. Cataldo, Giannicola Genovese, Jose A. Karam, Christopher G. Wood, Nizar M. Tannir, Pavlos Msaouel
Cancers.2021; 13(9): 2170. CrossRef
Response to systemic therapy in fumarate hydratase–deficient renal cell carcinoma
Lucia Carril-Ajuria, Emeline Colomba, Luigi Cerbone, Carmen Romero-Ferreiro, Laurence Crouzet, Brigitte Laguerre, Constance Thibault, Cécile Vicier, Guillermo de Velasco, Aude Fléchon, Carolina Saldana, Patrick R. Benusiglio, Brigitte Bressac-de Pailleret
European Journal of Cancer.2021; 151: 106. CrossRef
Hereditary Leiomyomatosis and Renal Cell Cancer: Recent Insights Into Mechanisms and Systemic Treatment
Congwang Zhang, Lijun Li, Yipeng Zhang, Changchun Zeng
Frontiers in Oncology.2021;[Epub] CrossRef
Hereditary leiomyomatosis and renal cell cancer presenting as urothelial carcinoma
Samuel B Reynolds, Rishi Charate, Quang L Nguyen, Padmini Moffett
Journal of Onco-Nephrology.2021; 5(3): 178. CrossRef
Das FH-defiziente Nierenzellkarzinom erweitert das Spektrum der papillären Tumoren in der Niere
N. Rupp, H. Moch
Der Pathologe.2021; 42(6): 560. CrossRef
To treat or not to treat: a clinical series of retinal arterial macroaneurysms
Wan-Hua Cho, Wei-Yu Chiang, Chih-Hsin Chen, Hsi-Kung Kuo
Medicine.2020; 99(5): e19077. CrossRef
Bevacizumab/erlotinib

Reactions Weekly.2020; 1798(1): 61. CrossRef
On the Shoulders of Giants: The Evolution of Renal Cell Carcinoma Treatment—Cytokines, Targeted Therapy, and Immunotherapy
Janice P. Dutcher, Ronan Flippot, Jaleh Fallah, Bernard Escudier
American Society of Clinical Oncology Educational Book.2020; (40): 418. CrossRef
Novel morphological and genetic features of fumarate hydratase deficient renal cell carcinoma in HLRCC syndrome patients with a tailored therapeutic approach
Nicolas Wyvekens, Nadejda Valtcheva, Axel Mischo, Birgit Helmchen, Thomas Hermanns, Matthias Choschzick, Andreas M. Hötker, Anita Rauch, Beda Mühleisen, Dilara Akhoundova, Achim Weber, Holger Moch, Niels J. Rupp
Genes, Chromosomes and Cancer.2020; 59(11): 611. CrossRef
Fumarate hydratase as a therapeutic target in renal cancer
Priyanka Kancherla, Michael Daneshvar, Rebecca A. Sager, Mehdi Mollapour, Gennady Bratslavsky
Expert Opinion on Therapeutic Targets.2020; 24(9): 923. CrossRef
Construct a circRNA/miRNA/mRNA regulatory network to explore potential pathogenesis and therapy options of clear cell renal cell carcinoma
Shuheng Bai, YinYing Wu, Yanli Yan, Shuai Shao, Jiangzhou Zhang, Jiaxin Liu, Beina Hui, Rui Liu, Hailin Ma, Xiaozhi Zhang, Juan Ren
Scientific Reports.2020;[Epub] CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Bevacizumab Plus Erlotinib Combination Therapy for Advanced Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Multicenter Retrospective Analysis in Korean Patients

Cancer Res Treat. 2019;51(4):1549-1556. Published online March 25, 2019

DOI: https://doi.org/10.4143/crt.2019.086

XML Download

Figure

Bevacizumab Plus Erlotinib Combination Therapy for Advanced Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Multicenter Retrospective Analysis in Korean Patients

Fig. 1. Waterfall plots depicting change from baseline in sum of diameters for target lesions in patients with hereditary leiomyomatosis and renal cell carcinoma–associated renal cell carcinoma treated with bevacizumab plus erlotinib (n=9). SD, stable disease; PR, partial response.

Fig. 2. Kaplan-Meier curve for progression-free survival (PFS) and overall survival (OS) in patient with hereditary leiomyomatosis and renal cell carcinoma–associated renal cell carcinoma treated with bevacizumab plus erlotinib.

Fig. 1.

Fig. 2.

Bevacizumab Plus Erlotinib Combination Therapy for Advanced Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Multicenter Retrospective Analysis in Korean Patients

Characteristic	No. (%) (n=10)
Age, median (range, yr)	41 (27-52)
Sex
Male	9 (90)
Female	1 (10)
Tumor histology at the time of initial diagnosis
Papillary RCC	8 (80)
Non-classified	2 (20)
Disease status at the time of initial diagnosis
Localized	3 (30)
Locally advanced	2 (20)
Metastatic	5 (50)
Nephrectomy	6 (60)
Line of bevacizumab and erlotinib
1st	4 (40)
2nd	1 (10)
3rd or more	5 (50)
IMDC prognostic group
Favorable	1 (10)
Intermediate	5 (50)
Poor	4 (40)
Karnofsky performance status (%)
100-90	2 (20)
80-70	5 (50)
< 70	3 (30)
Metastatic sites
Lymph nodes	9 (90)
Liver	8 (80)
Bone	7 (70)
Lung	6 (60)
Adrenal gland	3 (30)
No. of metastatic organs
1	0
2	3 (30)
3	1 (10)
4 or more	6 (60)

No.	Dx/Tx year	1st line	BR	TTP (mo)	2nd line	BR	TTP (mo)	3rd line	BR	TTP (mo)	4th line	BR	TTP (mo)	5th line	BR	TTP (mo)
1	2012/2013	Tem	PD	2.5	Axi	PR	24.8	Bev/Erlo	SD	6.5	Nivo/Pazo	SD	6.0	Ipi/Nivo	PD	0.2
2	2014/2014	Tem	PD	1.0	Axi	PD	0.6	Gem/Cis	PD	1.2	Ipi/Nivo	PD	0.5	Bev/Erlo	SD	4.1^a)
3	2015/2015	Tem	SD	4.8	Axi	PD	1.7	Bev/Erlo	PR	21.3	-	-	-	-	-	-
4	2015/2016	Tem	PD	2.3	Axi	PR	9.7	Bev/Erlo	SD	16.3+	-	-	-	-	-	-
5	2016/2018	Bev/Erlo	SD	6.1^a)	-	-	-	-	-	-	-	-	-	-	-	-
6	2017/2017	Sun	SD	5.5	Bev/Erlo	PR	13.3	-	-	-	-	-	-	-	-	-
7	2018/2018	Bev/Erlo	NE	0.6^b)	-	-	-	-	-	-	-	-	-	-	-	-
8	2018/2018	Bev/Erlo	PR	6.6+	-	-	-	-	-	-	-	-	-	-	-	-
9	2018/2018	Tem	PD	2.1	Nivo	PD	1.7	Bev/Erlo	PR	1.94+	-	-	-	-	-	-
10	2018/2018	Bev/Erlo	PR	11.0+	-	-	-	-	-	-	-	-	-	-	-	-

	Value
Best overall response, n (%)
CR	0
PR	5 (50)
SD	4 (40)
PD	0
NE	1 (10)
ORR (95% CI, %)	50 (24-76)
DCR (95% CI, %)	90 (60-98)
Median PFS (95% CI, mo)	13.3 (0.0-26.9)
Median OS (mo)^a)	14.1

	Any grade	Grade 3 or more
Any adverse event	10 (100)	2 (20)
Hematologic toxicity
Anemia	2 (20)	0
Neutropenia	0	0
Thrombocytopenia	0	0
Non-hematologic toxicity
Acneiform eruption	7 (70)	1 (10)
Hypertension	5 (50)	0
Proteinuria	4 (40)	0
ALT increased	4 (40)	0
Dry skin	4 (40)	0
Diarrhea	3 (30)	0
Fatigue	3 (30)	0
Creatinine increased	3 (30)	0
Mucositis, oral	2 (20)	0
Anorexia	2 (20)	0
Insomnia	2 (20)
Hyperbilirubinemia	1 (10)	0
Gastrointestinal bleeding	1 (10)	1 (10)^a)
Dry eye	1 (10)	0
Neuropathy	1 (10)	0
Wound dehiscence	1 (10)	0
Epistaxis	1 (10)	0
Hand-foot syndrome	1 (10)	0

Table 1. Baseline patient characteristics

RCC, renal cell carcinoma; IMDC, International Metastatic Renal Cell Carcinoma Database Consortium.

Table 2. History of systemic treatments and their outcomes

The patients were treated with bevacizumab plus erlotinib beyond radiologic progression for 9.2 months (case 2) and 0.4 month (case 5), respectively,

The patient died of gastrointestinal bleeding without disease progression.

Table 3. Treatment efficacy of bevacizumab plus erlotinib in patients with HLRCC-associated RCC (n=10)

The 95% CI was not calculated due to small number of events.

Table 4. Adverse events of bevacizumab and erlotinib (n=10)

Values are presented as number (%). ALT, alanine aminotransferase.

The patient died of grade 5 gastrointestinal bleeding.